Skip to main content
TipRanks
Go Ultimate75% OFF

Oramed Pharm (ORMP) AI Stock Analysis

533 Followers
ORMP

Oramed Pharm

(NASDAQ:ORMP)

Select Model
Rating:51Neutral
Price Target:$3.50â–¼(-1.96% Downside)
Action:reiterated
Date:11/20/26

Oramed is a pre-commercial biotech whose value rests on its balance sheet rather than its operations. A debt-free structure with $339.1M in equity and sharply reduced cash burn provides a long runway and low financial risk, but there is essentially no revenue, the core business remains loss-making, and reported profits are accounting-driven rather than cash-generating. Technical signals compound the caution, with the price below all key moving averages and a negative MACD. The sub-2x P/E is optically attractive but distorted by non-operating gains, and there is no dividend. The result is a below-average score reflecting solid capitalisation offset by weak operating fundamentals, negative price momentum, and a value proposition dependent on clinical execution.

Positive Factors
Strong balance sheetVery low leverage and substantial equity provide financial flexibility to fund research, absorb operating volatility, and pursue the oral therapeutics platform without significant debt pressure. This capitalization is a durable support while the company works toward commercial validation.
Negative Factors
Minimal commercial revenue and operating lossesThe company has not established a stable commercial revenue base, while recurring operating losses show that the core business is not yet self-funding. This leaves future value dependent on successful development and eventual commercialization rather than demonstrated operating earnings.

Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%ORMP+33.01%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$155.24M
Dividend Yield
―
Average Volume (3M)
173.53K
Price to Earnings (P/E)
1.0
Beta (1Y)
0.47
Revenue Growth
-100.00%
EPS Growth
238.88%
Country
US
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypep...

Oramed Pharm Financial Statement Overview

Summary

A fortress-like balance sheet (score 86) is the clear strength: $339.1M of equity funds roughly 99% of assets, total debt is a negligible $1.5M after clearing the prior $51.6M load, leaving virtually no refinancing risk and a long runway. However, the income statement (38) and cash flow (41) remain weak — there is effectively no product revenue (zero in the TTM period), the core operation still loses money (-$12.1M TTM operating result), and the headline $154.8M TTM net income comes from non-operating/non-cash gains rather than the business, confirmed by negative operating cash flow of -$3.2M. The redeeming trend is a dramatic reduction in burn from -$28.7M in 2022 to low single-digit millions today.

Income Statement

38Negative

Balance Sheet

86Very Positive

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Sep 2023Dec 2022Aug 2021
Income Statement
Total Revenue02.00M01.34M2.70M2.70M
Gross Profit-91.00K13.00K01.34M2.70M2.70M
EBITDA151.83M75.44M-14.87M7.32M-40.54M-24.15M
Net Income174.87M64.05M-19.06M5.53M-37.76M-22.24M
Balance Sheet
Total Assets369.64M230.86M155.28M220.55M161.64M128.00M
Cash, Cash Equivalents and Short-Term Investments50.61M125.89M141.93M162.05M155.72M94.14M
Total Debt733.00K825.00K372.00K51.62M894.00K533.00K
Total Liabilities52.17M31.12M9.93M57.66M10.49M11.48M
Stockholders Equity317.47M199.74M146.26M163.82M151.81M115.77M
Cash Flow
Free Cash Flow-5.01M-11.08M-8.43M-10.55M-29.20M-21.56M
Operating Cash Flow-5.21M-9.14M-8.41M-10.29M-28.70M-21.18M
Investing Cash Flow21.50M5.44M105.82M-73.04M30.21M-22.26M
Financing Cash Flow-16.68M-4.74M-52.04M51.98M11.56M101.39M

Oramed Pharm Technical Analysis

Technical Analysis SentimentNegative
Last Price3.57

Price Trends

50DMA4.25Negative
100DMA4.36Negative
200DMA4.07Negative

Market Momentum

MACD-0.14Positive
RSI33.76Neutral
STOCH15.96Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 3.97, below the 50-day MA of 4.25, and below the 200-day MA of 4.07, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 33.76 is Neutral, neither overbought nor oversold. The STOCH value of 15.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.A substantial majority of our assets consists of our investment in Alpha Tau, and a decline in the market price of Alpha Tau's ordinary shares, or our inability to sell those shares at favorable prices, would materially adversely affect our financial condition and results of operations.Q3, 2026
2.Scilex has not paid its obligations under the Tranche A Note and the Tranche B Note when originally due, and we may be unable to recover the amounts owed to us or to realize the value of our collateral.Q3, 2026
3.Our NIS-denominated loan to Hapisga and our other NIS-denominated assets and commitments expose us to foreign currency exchange rate fluctuations and to concentration risk.Q3, 2026

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ORMP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ORMPORMP51Neutral$160.46M1.0252.95%―-100.00%238.88%
SPRBSPRB41Neutral$116.37M-1.09-118.22%―-100.00%58.95%
ALXOALXO40Underperform$131.86M-1.22-73.35%――56.61%
WHWKWHWK40Underperform$184.11M-2.82-55.66%―-100.00%-825.52%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%ORMPWHWKALXOSPRBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ORMP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ORMPOramed Pharmaceuticals Inc3.571.1647.89%
WHWKWhitehawk Therapeutics, Inc.3.070.8638.91%
ALXOAlx Oncology Holdings, Inc.1.06-0.45-29.80%
SPRBSpruce Biosciences, Inc.38.00-69.00-64.49%

Oramed Pharm Corporate Events

Legal Proceedings

No Recent Events Reported for Oramed Pharmaceuticals

Negative
Nov 19, 2026

Oramed Pharmaceuticals Inc. was the company involved in a Delaware stockholder action concerning its bylaws. On February 20, 2026, a purported stockholder filed a putative class action alleging that provisions governing stockholder action by written...

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Oramed Pharm Shareholders Back Governance and Incentive Plan

Positive
Sep 17, 2026

At its Annual Meeting of Stockholders held on September 15, 2026, Oramed Pharm shareholders re-elected all incumbent directors to serve until the next annual meeting and ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026